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LETTERS TO THE EDITORLATE LEFTATRIAL
THROMBOSIS OFAN
AMPLATZER PATENT
FORAMEN OVALE OCCLUDER
MAY BE THE RESULT OF
KOUNIS HYPERSENSITIVITY-
ASSOCIATED SYNDROME
To the Editor:
In the very interesting report by
Klotz and colleagues1 published in
this Journal, a patient with a patent fo-
ramen ovale that was successfully oc-
cluded with an Amplatzer occluder
had a large thrombosis develop on
the atrial disk of the device 33 months
after the initial implantation. Al-
though Klotz and colleagues1 did not
refer to the etiology of thrombus for-
mation, several such causes have
been reported, including incorrect
device placement, device size, device
instability, anticoagulation, and anti-
platelet therapy monitoring.
The Amplatzer closure device is
made from nitinol, which is a nickel-
titanium alloy. Nickel allergy is quite
common, and in a recent report the
overall prevalence was found to be
24.6%. Titanium hypersensitivity, al-
though low, has been seen in dental
procedures and induces implant fail-
ure.2 The described patient received
also aspirin and warfarin on several
occasions, both of which are well-
known antigenic compounds.3 It is
known that mast cells bring, on their
surface, 500,000 to 1 million IgE mol-
ecules, and to degranulate they need
2000 of these molecules, which is
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can be made by antigens of different
specificities, as happens in patients
with metal device implantation. It
looks likely that the more antigens to
which a patient with metal device im-
plantation, is exposed the more easily
and quickly the degranulation occurs.2
Nickel and titanium ions acting as
antigens can activate platelets to
release proinflammatory, prothrom-
botic, adhesive, and aggregatory
mediators to induce thrombus forma-
tion.4 Platelet activation is taking
place through stimulation of some
known receptors in the platelet sur-
face, such as receptors for adenosine
diphosphate, for thromboxane, for
thrombin, for serotonin, and for epi-
nephrine, and through some less-
known receptors, such as receptors
for platelet activating factor, for hista-
mine, and for high-affinity and low-
affinity IgE receptors FCεRI and
FCεRII.2
Thrombus formation after left atrial
appendage occulsion with an Amplat-
zer cardiac plug device can occur
months after the procedure. Nickel
allergy to intracardiac devices has
caused systemic allergic reactions
confirmed by patch tests to nitinol,
which necessitated the removal of
those devices. A device syndrome
resembling Kounis syndrome and
consisting of chest discomfort, exer-
tional dyspnea, palpitations, asthenia,
atrial fibrillation was reported in 8 of
9 patients in a series after Amplatzer
implantation. Those patients had pos-
itive patch skin test reactions to
nickel.5
Although the rate of thrombosis
complicating such devices might be
low, we are still in the learning curve,
and additional research is needed to
prevent and treat such consequences.
We recommend avoidance of metal
device implantation in patients with
known hypersensitivity or contraindi-
cation to any structurally related
compound and to drugs these patients
would need to take after
implantation.ardiovascular Surgery c July 2012Nicholas G. Kounis,
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My coauthors and I read with
great interest the Letter to the Editor
by Kounis and colleagues regarding
our case report of a left atrial throm-
bosis of an Amplatzer patent fora-
men ovale (PFO) occluder (St Jude
Medical, St Paul, Minn) 33 months
after implantation.1 Kounis and col-
leagues hypothesized that this
thrombosis could the result of the
Kounis hypersensitivity-associated
syndrome. This syndrome describes,
among others, an allergic reaction
to intracardiac metal devices (such
as PFO occluders and stents) con-
taining nickel or other metals.2
We appreciate the input fromKounis
and colleagues, which might give
Letters to the Editorimportant hints to our case and future
device applications. Regarding our
case, we explicitly asked the patient
for any known allergies at the time of
the operation and repeated this query
after the comment from Kounis and
colleagues. The patient denied any al-
lergies; however, a skin test for sensi-
tivity to nickel or other metals was
not performed. In addition, after initial
interventional Amplatzer PFO oc-
cluder implantation, the patient was
without any signs of discomfort, palpi-
tations, dyspnea, headache, pericardial
effusion, or conspicuously altered lab-
oratory values, the main symptoms
of Kounis hypersensitivity-associated
syndrome, for almost 33 months. The
symptom that precipitated readmission
to the hospital was a stroke, which
was most likely due to the thrombus
formation on the atrial disk of the
Amplatzer device. We cannot rule
out, the possibility that the Kounis
hypersensitivity-associated syndrome
played some role in development of
this thrombus formation; however,
the histologic examination of the ex-
planted device and thrombus did not
reveal any inflammatory cells. In
a multicenter-study of PFO closure
device explants, the rate of explants
was 0.28%.3 Most of these explants
were due to persistent or unknown
chest pain, and half of these patients
had a known nickel allergy. In addition
it is shown, that in patients with known
nickel allergy the rate of chest discom-
fort and palpitations is significantly
increased after PFO device closure.4
None of these signs were found in
our patient.
We fully agree with Kounis and col-
leagues that a possible nickel allergy
should be ruled out before elective im-
plantation of intracardiac metal de-
vices. Otherwise, the patient should
be made aware of the possibility of
device explantation when informed
consent is obtained.
Stefan Klotz, MD
Department of Cardiac and Thoracic
Vascular SurgeryThe JournalUniversity Hospital L€ubeck
L€ubeck, GermanyReferences
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ULTRASOUND–GUIDED
MEDIASTINAL LYMPH NODE
NEEDLE ASPIRATION IN
NON–SMALL CELL LUNG
CANCER: FROM THEORY TO
PRACTICE
To the Editor:
We read with pleasure the article by
Lee and colleagues.1 Endobronchial
ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is a new
diagnostic technique that provides
a minimally invasive option for medi-
astinal staging in patients with lung
cancer. This technique was described
by Krasnik and colleagues2 in 2003
and rapidly gained the interest of the
scientific community. Nonrandomized
studies demonstrate that EBUS-TBNA
affords excellent diagnostic perfor-
mance with a sensitivity ranging from
70% to 99% and a negative predictive
value up to 98%.3 Those excellent pre-
liminary results convinced the Ameri-
can College of Chest Physicians to
advocate EBUS-TBNA to stage the
mediastinum only 4 years after the first
description of the technique.
In 2006, we had the opportunity to
use the first dedicated bronchoscope
imported to Italy, and the potential
of EBUS-TBNA was immediately
obvious. The short learning curve,of Thoracic and Cardiovascular Surgehigh diagnostic accuracy, minimal
invasiveness, and possible surgical
sparing encouraged us to use EBUS-
TBNA even outside of lung cancer
staging.4
In a paradoxical way, the excellence
of the preliminary results delayed the
production of randomized studies, and
to date only Annema and colleagues,5
pioneers in endobronchial ultrasound,
published the randomized clinical trial,
ASTER (Assessment of Surgical Stag-
ing Versus Endosonographic Ultra-
sound in Lung Cancer). In the aseptic
world of scientific trials, the report by
Lee and colleagues1 attracts our atten-
tion for its ability to focus interest on
clinical practice. The brilliant results
reported by the authors demonstrate
the high diagnostic value of EBUS-
TBNA and the undoubtable skill of
the operators. We do recommend rapid
on-site evaluation of the specimen be-
cause it can decrease the rate of inade-
quate tests.
Reports with strong clinical charac-
teristics, as well as randomized trials,
are needed to validate EBUS-TBNA,
especially for its potential capability
of avoiding unnecessary surgery.
Mario Nosotti, MD
Matilde De Simone, MD, PhD
Ugo Cioffi, MD, PhD
Department of Surgery
Fondazione IRCCS Ospedale
Maggiore Policlinico
University of Milan
Milan, Italy
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